Ownership Change to Note: Resmed Inc (NYSE:RMD) Q2 2016 Sentiment

November 30, 2016 - By Peter Erickson   ·   0 Comments

Ownership Change to Note: Resmed Inc (NYSE:RMD)  Q2 2016 Sentiment

Sentiment for Resmed Inc (NYSE:RMD)

Resmed Inc (NYSE:RMD) institutional sentiment decreased to 1.09 in 2016 Q2. Its down -0.35, from 1.44 in 2016Q1. The ratio fall, as 186 funds increased or opened new holdings, while 129 decreased and sold their holdings in Resmed Inc. The funds in our partner’s database now have: 83.87 million shares, up from 81.90 million shares in 2016Q1. Also, the number of funds holding Resmed Inc in their top 10 holdings increased from 3 to 4 for an increase of 1. Sold All: 42 Reduced: 87 Increased: 150 New Position: 36.

ResMed Inc. is a holding company. The Company, through its subsidiaries, designs, makes and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The company has a market cap of $8.99 billion. The Firm develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories. It has a 25.25 P/E ratio. The Firm owns interest in Inova Labs Inc., a medical device firm specializing in the development and commercialization of oxygen therapy products.

The stock increased 2.47% or $1.5 during the last trading session, hitting $62.11. ResMed Inc. (NYSE:RMD) has risen 9.64% since April 27, 2016 and is uptrending. It has outperformed by 4.41% the S&P500.

Analysts await ResMed Inc. (NYSE:RMD) to report earnings on January, 19. They expect $0.70 earnings per share, up 1.45% or $0.01 from last year’s $0.69 per share. RMD’s profit will be $101.32 million for 22.18 P/E if the $0.70 EPS becomes a reality. After $0.62 actual earnings per share reported by ResMed Inc. for the previous quarter, Wall Street now forecasts 12.90% EPS growth.

According to Zacks Investment Research, “ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors.”

Halsey Associates Inc Ct holds 3.7% of its portfolio in ResMed Inc. for 263,058 shares. Matthews International Capital Management Llc owns 1.22 million shares or 3.38% of their US portfolio. Moreover, Professional Advisory Services Inc has 3.07% invested in the company for 212,520 shares. The Wisconsin-based Capital Investment Services Of America Inc. has invested 2.73% in the stock. West Coast Financial Llc, a California-based fund reported 75,749 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider purchases, and 25 sales for $23.07 million net activity.

ResMed Inc. (NYSE:RMD) Ratings Coverage

Ratings analysis reveals 36% of ResMed Inc’s analysts are positive. Out of 11 Wall Street analysts rating ResMed Inc, 4 give it “Buy”, 3 “Sell” rating, while 4 recommend “Hold”. The lowest target is $52 while the high is $66. The stock’s average target of $59.25 is -4.60% below today’s ($62.11) share price. RMD was included in 17 notes of analysts from August 3, 2015. On Tuesday, January 19 the stock rating was downgraded by Barclays Capital to “Underweight”. As per Monday, June 27, the company rating was downgraded by Needham. Morgan Stanley upgraded the shares of RMD in a report on Monday, August 3 to “Overweight” rating. Piper Jaffray downgraded ResMed Inc. (NYSE:RMD) on Wednesday, April 27 to “Neutral” rating. The firm has “Neutral” rating given on Tuesday, October 4 by JP Morgan. Credit Suisse upgraded the stock to “Outperform” rating in Friday, January 22 report. The rating was upgraded by Bank of America on Thursday, September 29 to “Buy”. The company was downgraded on Monday, September 19 by JP Morgan. The stock of ResMed Inc. (NYSE:RMD) has “Underweight” rating given on Thursday, April 7 by Barclays Capital. Macquarie Research upgraded the stock to “Neutral” rating in Thursday, April 28 report.

RMD Company Profile

ResMed Inc., incorporated on March 31, 1994, is a holding company. The Company, through its subsidiaries, designs, makes and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Firm develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories.

More recent ResMed Inc. (NYSE:RMD) news were published by: Prnewswire.com which released: “ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2017” on October 25, 2016. Also Forbes.com published the news titled: “ResMed Becomes Oversold” on September 23, 2016. Nasdaq.com‘s news article titled: “ResMed Inc. (RMD) Ex-Dividend Date Scheduled for November 08, 2016” with publication date: November 07, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>